Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-6529
Fax+1 614-293-9469
Dr. Otterson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Rush University Medical CenterResidency, Internal Medicine, 1986 - 1989
Georgetown University School of MedicineClass of 1986
Certifications & Licensure
OH State Medical License 1998 - 2024
MD State Medical License 1989 - 1999
IL State Medical License 1986 - 1990
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
Clinical Trials
- Capecitabine in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Nov 01
- Combination Chemotherapy in Treating Patients With Solid Tumors Start of enrollment: 2001 Jan 01
- Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer Start of enrollment: 2004 Apr 01
Publications & Presentations
PubMed
- Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.Annastasia Petouhoff, Ryan Hicks, Marium Husain, Rebecca Hoyd, Menglin Xu
Cancer Immunology, Immunotherapy. 2026-03-09 - Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.Mingjia Li, Daniel J Spakowicz, Songzhu Zhao, Hyunwoo Kwon, Kenneth Chian
Journal of Cancer. 2026-01-01 - Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy.Adam Khorasanchi, Mingjia Li, Songzhu Zhao, Lai Wei, Evelyn Goodyear
Lung Cancer. 2025-12-01
Journal Articles
- Identifying Patterns of Care for Elderly Patients with Non-Surgically Treated Stage III Non-Small Cell Lung Cancer: An Analysis of the National Cancer DatabaseKai He, Terence M Williams, John C Grecula, Eric D Miller, Erin M Bertino, David P Carbone, Peter G Shields, Jose G Bazan, Karl E Haglund, Gregory A Otterson, BioMed Central
Press Mentions
Targeted Therapy of Lung Cancer – Lung Cancer Targeted TherapyOctober 28th, 2015
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
